Skip to main content
Elsevier
View Cart
My account

Books in Immunopharmacology pharmacology

BooksJournals

    • The Diagnosis and Treatment of Protozoan Diseases

      • 1st Edition
      • May 29, 2024
      • Tarun Kumar Bhatt
      • English
      • Paperback
        9 7 8 0 4 4 3 1 9 1 6 1 9
      • eBook
        9 7 8 0 4 4 3 1 5 2 4 5 0
      The Diagnosis and Treatment of Protozoan Diseases discusses major protozoan diseases such as Malaria, Leishmaniasis, etc., including other clinically minor protozoan diseases. This book provides all essential information to professional researchers and medical personnel about the disease, causative organism, and their lifecycle, diagnostics, and treatments, including drugs and vaccine, resistance, and key points of future research. Infectious diseases are accountable for millions of deaths every year throughout the globe. Among them, significant contributors are protozoan parasites.Despite the many research group working on the various protozoan diseases, there are still major gaps to fill. The authors of this book have critically reviewed all the aspects of major protozoan diseases, their diagnostics, and treatments, including resistance.

    • Hemodynamics and Immune Defense

      • 2nd Edition
      • October 23, 2023
      • Michael J. Parnham + 2 more
      • English
      • eBook
        9 7 8 0 3 2 3 9 9 3 1 9 7
      Haemodynamics and Immune Defence: Discoveries in Pharmacology, Second Edition, Volume Three presents selected articles from the historic Discoveries in Pharmacology series that are enhanced with commentary from contemporary scholars who discuss the reception and importance of each chapter along with an updated bibliography on the subject and contributions from those involved in Nobel Prize winning discoveries and pioneering advancements in Pharmacology. This volume brings forth discussions on key discoveries in hemodynamics and immune defense, including chapters on penicillin by Dr. Selwyn and asthma by Dr. Brocklehurst. Academic and industry researchers in pharmacology and medicine, as well as advanced students in the area, will find this useful teaching tool and launch to new discoveries. Chapters can also be used to supplement course material in pharmacology and medical courses. It will also be of interest to those who are interested in the history of medicine.

    • Immune Rebalancing

      • 1st Edition
      • January 21, 2016
      • Diana Boraschi + 1 more
      • English
      • Paperback
        9 7 8 0 1 2 8 0 3 3 0 2 9
      • eBook
        9 7 8 0 1 2 8 0 3 3 3 6 4
      Immune Rebalancing: The Future of Immunosuppression summarizes the most promising perspectives of immunopharmacology, in particular in the area of immunosuppression by considering molecular pathways, personalized medicine, microbiome and nanomedicine. Modulation of immune responses for therapeutic purposes is a particularly relevant area, given the central role of anomalous immunity in diseases. These diseases vary from the most typically immune-related syndromes (autoimmune diseases, allergy and asthma, immunodeficiencies) to those in which altered immunity and inflammation define the pathological outcomes (chronic infections, tumours, chronic inflammatory and degenerative diseases, metabolic disorders, etc.

    • Immunopharmacology

      • 1st Edition
      • Volume 66
      • February 18, 2013
      • David J Webb
      • English
      • Hardback
        9 7 8 0 1 2 4 0 4 7 1 7 4
      • Paperback
        9 7 8 0 3 2 3 2 8 2 8 0 2
      • eBook
        9 7 8 0 1 2 4 0 5 1 8 4 3
      This new volume of Advances in Pharmacology explores the current state of Alzheimer's disease research and therapeutics. Chapters cover such topics as the B cell targeted therapies, Lymphotoxin family receptors in inflammation, and allergic inflammation and thymic stromal lymphopoietin. With a variety of chapters and the best authors in the field, the volume is an essential resource for pharmacologists, immunologists and biochemists alike.

    • Systemic Lupus Erythematosus

      • 5th Edition
      • October 29, 2010
      • Robert G. Lahita + 3 more
      • English
      • Hardback
        9 7 8 0 1 2 3 7 4 9 9 4 9
      • eBook
        9 7 8 0 0 8 0 9 6 1 7 1 2
      Systemic lupus erythematosus (S.L.E.), commonly called lupus, is a chronic autoimmune disorder that can affect virtually any organ of the body. In lupus, the body's immune system, which normally functions to protect against foreign invaders, becomes hyperactive, forming antibodies that attack normal tissues and organs, including the skin, joints, kidneys, brain, heart, lungs, and blood. Lupus is characterized by periods of illness, called flares, and periods of wellness, or remission. Because its symptoms come and go and mimic those of other diseases, lupus is difficult to diagnose. There is no single laboratory test that can definitively prove that a person has the complex illness. To date, lupus has no known cause or cure. Early detection and treatment is the key to a better health outcome and can usually lessen the progression and severity of the disease. Anti-inflammatory drugs, anti-malarials, and steroids (such as cortisone and others) are often used to treat lupus. Cytotoxic chemotherapies, similar to those used in the treatment of cancer, are also used to suppress the immune system in lupus patients. A new edition of this established and well regarded reference which combines basic science with clinical science to provide a translational medicine model. Systemic Lupus Erythematosus is a useful reference for specialists in the diagnosis and management of patients with SLE, a tool for measurement of clinical activity for pharmaceutical development and basic research of the disease and a reference work for hospital libraries.

    • Meyler's Side Effects of Drugs in Cancer and Immunology

      • 1st Edition
      • April 19, 2010
      • Jeffrey K. Aronson
      • English
      • Hardback
        9 7 8 0 4 4 4 5 3 2 6 7 1
      • Paperback
        9 7 8 0 4 4 4 5 6 2 0 6 7
      • eBook
        9 7 8 0 0 8 0 9 3 2 8 8 0
      Elsevier now offers a series of derivative works based on the acclaimed Meyler’s Side Effect of Drugs, 15th Edition. These individual volumes are grouped by specialty to benefit the practicing biomedical researcher and/or clinician. There has been significant progress in the development of targeted therapy drugs that act specifically on certain cancers, and that minimize damage to normal cells. Oncologists and cancer researchers will rely on this volume to determine effective drug treatments.

    • Immunopharmacology of Respiratory System

      • 1st Edition
      • October 18, 1995
      • Stephen T. Holgate
      • English
      • Hardback
        9 7 8 0 1 2 3 5 2 3 2 5 9
      • Paperback
        9 7 8 0 1 2 3 9 0 8 9 8 8
      • eBook
        9 7 8 0 0 8 0 5 3 4 5 5 8
      Immunopharmacology represents the boundary between the immune system and chemical mediators of the inflammatory and neuroendocrine responses. The subject as applied to the respiratory system embraces most of the common non-malignant lung diseases of which asthma and allied disorders are the most prevalent. An understanding of the underlying mechanisms of the disorders provides rationale for prevention and drug treatment as well as creating opportunities for novel drug development. Immunopharmacology of Respiratory System embraces all of these principles and should enable the reader to become rapidly updated in an area of medical importance.

    • Immunopharmacology of Epithelial Barriers

      • 1st Edition
      • February 21, 1994
      • English
      • Hardback
        9 7 8 0 1 2 2 8 8 0 3 0 8
      • eBook
        9 7 8 0 0 8 0 9 1 8 4 0 2
      The realisation that epithelial tissues are not simply passive barriers to the adsorption of materials into internal environments has brought about an enormous growth of investigation of mucosal functions and their active and passive protective roles. Epithelia are highly organized but complex structures, subserving numerous functions, including immunological defence. The use of pharmacological tools in these systems is increasing, which is improving our understanding of epithelial immunobiology. This volume adopts a step-by-step approach, whereby each chapter builds upon the previous one, progressively adding important foundation information, culminating in a series of chapters concerning particular epithelia, including respiratory, gastrointestinal, renal and ocular. The result is a comprehensive but integrated treatise of epithelial function and its immunopharmacology, which aims to serve as an appropriate starting point at which the clinical pulmonologist and the research scientist can obtain an appreciation of some aspects of epithelial immunopharmacology as they are currently understood.

    • Immunopharmacology of Joints and Connective Tissues

      • 1st Edition
      • January 7, 1994
      • English
      • Hardback
        9 7 8 0 1 2 2 0 6 3 4 5 9
      • eBook
        9 7 8 0 0 8 0 9 1 7 5 8 0
      The consequences for diseases involving the immune system such as AIDS, and chronic inflammatory diseases such as bronchial asthma, rheumatoid athritis, and atherosclerosis, now account for a considerable economic burden to governments worldwide. In response there has been an enormous research effort investigating the basic mechanisms underlying such diseases, and a tremendous drive to identify novel therapeutic applications for their preventions and treatment. Though a plethora of immunological studies have been published in recent years, little has been written about the implications of such research for drug development. As a consequence, this area has not gained the prominence of other new fields such as molecular pharmacology or neuropharmacology, and a focal information source for many pharmacologists interested in diseases of the immune system remains unpublished. The Handbook of Immunopharmacology series provides such a source through the commissioning of a comprehensive collection of volumes on all aspects immunopharmacology. Editors have been sought after for each volume who are not only active in their respective areas of expertise, but who also have distinctly pharmacological bias to their research. The series follows three main themes, each represented by volumes on individual component topics. The first covers each of the major cell types and classes of inflammatory responses that can affect them ("Systems"). The third covers different classes of diseases as well as those under development ("Drugs").

    • Immunopharmacology of the Heart

      • 1st Edition
      • October 21, 1993
      • English
      • Hardback
        9 7 8 0 1 2 2 0 0 2 4 5 8
      • eBook
        9 7 8 0 0 8 0 9 1 7 5 6 6
      This volume sets out to consider a range of cardiac diseases for which drugs may play a therapeutic role by virtue of their effects on aspects of the immune system. The book reviews diseases of the heart which may involve an immunopharmacologica... component, and methods and techniques for the study of physiological and biochemical functions in the heart. An important focus is the immunopharmacology of the coronary vascular endothelium and the role of cellular and biochemical components of the immune system in the pathogenesis of atherosclerosis. The content also includes a review of the use of immunologically relevant agents in the setting of cardiac transplantation from aclinical perspective. Immunotherapy has a definite role to play in cardiology to a greater or lesser extent than other forms of intervention, depending on the type of cardiac disease. Immunopharmacology of the Heart aims to identify and clarify this role and points to potential developments of the future. Immunopharmacology of the Heart is a volume for the SYSTEMS theme of The Handbook of Pharmacology. In common with all other volumes it contains standardized illustrations and terms/abbreviations (glossaries of illustrations and terms published at the back of the volume). Other topics covered include: Leukocytes and their role in ischaemic heart disease. Complement activation. Sudden cardiac death. The stunned myocardium and reperfusion injury.